Monday, November 9, 2015
- 4:30PM-6:00PM
-
Abstract Number: 2084
Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Modulates Bone Resorption in Inflammatory Arthritis and Fracture Repair
Biology and Pathology of Bone and Joint: Bone Remodeling- 4:30PM-6:00PM
-
Abstract Number: 2095
Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study
Epidemiology and Public Health III: Risk Factors, Treatment and Outcomes of Gout and OA- 4:30PM-6:00PM
-
Abstract Number: 2172
Distribution of Clinical Osteoarthritis and Associations to Health-Related Quality of Life in a Population-Based Osteoarthritis Cohort
ARHP III: Epidemiology and Public Health- 4:30PM-6:00PM
-
Abstract Number: 2149
Dose Reduction Compared with Standard Dosing for Maintenance of Remission in Patients with Spondyloarthropathies and Clinical Remission with Anti-TNF: A Randomised Real-Life Trial
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment:Treatment of PsA and SpA- 4:30PM-6:00PM
-
Abstract Number: 2140
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy IV: Safety of Targeted Therapies- 4:30PM-6:00PM
-
Abstract Number: 2105
Drug Survival and Cost Effectiveness in Patients on Reduced Dose Anti-TNF: Results of a 4 Year Prospective Observational Study
Health Services Research II: Rheumatoid Arthritis Treatment and Healthcare Utilization- 4:30PM-6:00PM
-
Abstract Number: 2144
Efficacy and Safety of Different Dose Regimens of a Selective IL-23p19 Inhibitor (BI 655066) Compared with Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis with and without Psoriatic Arthritis
Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment:Treatment of PsA and SpA- 4:30PM-6:00PM
-
Abstract Number: 2127
Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Subclinical Coronary Atherosclerosis Is Higher Among Rheumatoid Arthritis Patients with the Lowest Circulating Low Density Lipoprotein Concentrations Compared with Controls
Rheumatoid Arthritis - Clinical Aspects III - Cardiovascular Disease and RA- 4:30PM-6:00PM
-
Abstract Number: 2119
Findings and Therapeutic Impact of Magnetic Resonance Imaging (MRI) Studies for Patients with Lower Back Pain with Neurologic Symptoms. Are We Choosing Wisely?
Orthopedics, Low Back Pain and Rehabilitation- 4:30PM-6:00PM
-
Abstract Number: 2090
Gender-Specific Pathways Linking Arthritis, Activity Limitation and Incident Heart Disease: A Causal Mediation Analysis of the Canadian Longitudinal National Population Health Survey
Epidemiology and Public Health III: Risk Factors, Treatment and Outcomes of Gout and OA- 4:30PM-6:00PM
-
Abstract Number: 2099
Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout
Genetics, Genomics and Proteomics- 4:30PM-6:00PM
-
Abstract Number: 2102
Higher Persistence and Adherence with Combination Therapy with Tumor Necrosis Factor Inhibitor+Methotrexate Combination Versus Triple Therapy in US Veterans with Rheumatoid Arthritis
Health Services Research II: Rheumatoid Arthritis Treatment and Healthcare Utilization- 4:30PM-6:00PM
-
Abstract Number: 2114
Higher Total Knee Arthroplasty Revision Rates in Black Americans: A Systematic Literature Review and Meta-Analysis
Orthopedics, Low Back Pain and Rehabilitation- 4:30PM-6:00PM
-
Abstract Number: 2101
HLA Associations in Mothers of Children with Cardiac Manifestations of Neonatal Lupus
Genetics, Genomics and Proteomics- 4:30PM-6:00PM
-
Abstract Number: 2097
HLA-B27 Expression Profoundly Shapes the Host-Microbiota Metabolome